Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is presenting eight scientific posters at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, running October 21-23, 2026.

The presentations cover products including HArmonyCa™, Juvéderm®, Skinvive™ and Botox® Cosmetic. HArmonyCa™, which recently launched in the United Arab Emirates, is a hybrid facial injectable combining hyaluronic acid and calcium hydroxyapatite.

One poster presents a subgroup analysis of eight patients using GLP-1 weight-loss medications who were treated with HArmonyCa™. All eight participants showed visible midface improvement at three months, according to the press release. The findings are described as preliminary evidence for addressing facial volume changes in patients undergoing GLP-1 medical weight loss.

Additional data being presented include 24-month clinical results from a multicenter randomized study on HArmonyCa™ for midface soft tissue augmentation, patient-reported outcomes on neck appearance following Skinvive™ treatment, and a sub-analysis of Middle Eastern patients receiving long-term repeated Botox® Cosmetic treatment for upper facial lines. The majority of patients in the Botox® Cosmetic study reported satisfaction with long-term treatment of upper forehead lines.

On October 21, the Allergan Medical Institute is hosting a symposium on the AA Signature™ Lift-Up multimodal approach featuring a live technique showcase. On October 22, Allergan Aesthetics' global medical affairs team is hosting a separate symposium on neurotoxin science and long-term Botox® Cosmetic evidence.